Kao-Ping Chua1, Chad M Brummett2,3, Rena M Conti4, Amy Bohnert5,6. 1. Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan Medical School, Ann Arbor. 2. Division of Pain Medicine, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor. 3. Michigan Opioid Prescribing Engagement Network, Ann Arbor. 4. Questrom School of Business, Institute for Health System Innovation and Policy, Department of Markets, Public Policy, and Law, Boston University, Boston, Massachusetts. 5. Veterans Affairs Center for Clinical Management Research, Veterans Affairs Ann Arbor Health System, Ann Arbor, Michigan. 6. Department of Psychiatry, University of Michigan Medical School, Ann Arbor.
Abstract
Importance: Safe opioid prescribing practices are critical to mitigate the risk of prescription opioid overdose in adolescents and young adults. However, studies that examine opioid prescribing patterns associated with prescription opioid overdose have mostly focused on older adults. The generalizability of these studies to adolescents and young adults is unclear. Objective: To identify opioid prescribing patterns associated with prescription opioid overdose in adolescents and young adults. Design, Setting, and Participants: This retrospective cohort study assessed privately insured patients aged 12 to 21 years with opioid prescription claims in the IBM MarketScan Commercial Claims and Encounters database between July 1, 2009, and October 1, 2017, and no cancer diagnosis. Data analysis was performed from January 1 to April 30, 2019. Main Outcomes and Measures: The outcome was a treated opioid overdose as indicated by diagnosis codes. On the basis of days supplied, opioid prescription claims were converted to person-days (the unit of analysis) on which opioid exposure would occur if patients took medications as prescribed. Logistic regression with clustered SEs at the patient level was used to model the occurrence of overdose on a person-day as a function of daily opioid dosage category (<30, 30-59, 60-89, 90-119, or ≥120 morphine milligram equivalents), concurrent benzodiazepine use, and extended-release or long-acting opioid use. Regressions controlled for demographic characteristics, year, opioid use within 180 days, and comorbidities (mental health disorder, substance use disorder, and other chronic condition). Results: A total of 2 752 612 patients (mean [SD] age at cohort entry, 17.2 [2.5] years; 1 451 918 [52.8%] female) participated in the study. Patients had 4 686 355 opioid prescription claims, corresponding to 21 605 444 person-days. Overdose occurred on 255 person-days among 249 patients (0.01% of the sample). Each increase in daily opioid dosage category was associated with higher overdose risk (adjusted odds ratio [AOR], 1.18; 95% CI, 1.05-1.31). Compared with no use, both concurrent benzodiazepine use (AOR, 1.83; 95% CI, 1.24-2.71) and extended-release or long-acting opioid use (AOR, 2.01; 95% CI, 1.16-3.46) were associated with increased overdose risk. Conclusions and Relevance: The findings suggest that when prescribing opioids to adolescents and young adults, practitioners could potentially mitigate overdose risk by using the lowest effective daily dosage, avoiding concurrent opioid and benzodiazepine prescribing, and relying on short-acting opioids. Findings are broadly consistent with prior opioid safety studies focused on older adults.
Importance: Safe opioid prescribing practices are critical to mitigate the risk of prescription opioid overdose in adolescents and young adults. However, studies that examine opioid prescribing patterns associated with prescription opioid overdose have mostly focused on older adults. The generalizability of these studies to adolescents and young adults is unclear. Objective: To identify opioid prescribing patterns associated with prescription opioid overdose in adolescents and young adults. Design, Setting, and Participants: This retrospective cohort study assessed privately insured patients aged 12 to 21 years with opioid prescription claims in the IBM MarketScan Commercial Claims and Encounters database between July 1, 2009, and October 1, 2017, and no cancer diagnosis. Data analysis was performed from January 1 to April 30, 2019. Main Outcomes and Measures: The outcome was a treated opioid overdose as indicated by diagnosis codes. On the basis of days supplied, opioid prescription claims were converted to person-days (the unit of analysis) on which opioid exposure would occur if patients took medications as prescribed. Logistic regression with clustered SEs at the patient level was used to model the occurrence of overdose on a person-day as a function of daily opioid dosage category (<30, 30-59, 60-89, 90-119, or ≥120 morphine milligram equivalents), concurrent benzodiazepine use, and extended-release or long-acting opioid use. Regressions controlled for demographic characteristics, year, opioid use within 180 days, and comorbidities (mental health disorder, substance use disorder, and other chronic condition). Results: A total of 2 752 612 patients (mean [SD] age at cohort entry, 17.2 [2.5] years; 1 451 918 [52.8%] female) participated in the study. Patients had 4 686 355 opioid prescription claims, corresponding to 21 605 444 person-days. Overdose occurred on 255 person-days among 249 patients (0.01% of the sample). Each increase in daily opioid dosage category was associated with higher overdose risk (adjusted odds ratio [AOR], 1.18; 95% CI, 1.05-1.31). Compared with no use, both concurrent benzodiazepine use (AOR, 1.83; 95% CI, 1.24-2.71) and extended-release or long-acting opioid use (AOR, 2.01; 95% CI, 1.16-3.46) were associated with increased overdose risk. Conclusions and Relevance: The findings suggest that when prescribing opioids to adolescents and young adults, practitioners could potentially mitigate overdose risk by using the lowest effective daily dosage, avoiding concurrent opioid and benzodiazepine prescribing, and relying on short-acting opioids. Findings are broadly consistent with prior opioid safety studies focused on older adults.
Authors: Calista M Harbaugh; Jay S Lee; Hsou Mei Hu; Sean Esteban McCabe; Terri Voepel-Lewis; Michael J Englesbe; Chad M Brummett; Jennifer F Waljee Journal: Pediatrics Date: 2017-12-04 Impact factor: 7.124
Authors: Jane A Gwira Baumblatt; Caleb Wiedeman; John R Dunn; William Schaffner; Leonard J Paulozzi; Timothy F Jones Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: Tamara D Simon; Mary Lawrence Cawthon; Susan Stanford; Jean Popalisky; Dorothy Lyons; Peter Woodcox; Margaret Hood; Alex Y Chen; Rita Mangione-Smith Journal: Pediatrics Date: 2014-05-12 Impact factor: 7.124
Authors: Nabarun Dasgupta; Michele Jonsson Funk; Scott Proescholdbell; Annie Hirsch; Kurt M Ribisl; Steve Marshall Journal: Pain Med Date: 2016-01 Impact factor: 3.750
Authors: Cecilia P Chung; S Todd Callahan; William O Cooper; Katherine T Murray; Kathi Hall; Judith A Dudley; C Michael Stein; Wayne A Ray Journal: BMC Res Notes Date: 2015-07-04
Authors: Gabriel A Brat; Denis Agniel; Andrew Beam; Brian Yorkgitis; Mark Bicket; Mark Homer; Kathe P Fox; Daniel B Knecht; Cheryl N McMahill-Walraven; Nathan Palmer; Isaac Kohane Journal: BMJ Date: 2018-01-17
Authors: Kao-Ping Chua; Jennifer F Waljee; Vidhya Gunaseelan; Romesh P Nalliah; Chad M Brummett Journal: Am J Prev Med Date: 2022-03 Impact factor: 5.043
Authors: Sara E Heins; Christine Buttorff; Courtney Armstrong; Rosalie Liccardo Pacula Journal: Drug Alcohol Depend Date: 2021-09-22 Impact factor: 4.492
Authors: William T Basco; Jenna L McCauley; Jingwen Zhang; Patrick D Mauldin; Kit N Simpson; Khosrow Heidari; Justin E Marsden; Sarah J Ball Journal: Pediatrics Date: 2021-02-01 Impact factor: 7.124
Authors: Patrick D Quinn; Zheng Chang; Matthew J Bair; Martin E Rickert; Robert D Gibbons; Kurt Kroenke; Brian M D'Onofrio Journal: Pain Date: 2022-04-01 Impact factor: 7.926
Authors: Scott E Hadland; Sarah M Bagley; Mam Jarra Gai; Joel J Earlywine; Samantha F Schoenberger; Jake R Morgan; Joshua A Barocas Journal: Addiction Date: 2021-04-06 Impact factor: 7.256